Drug Profile
Docetaxel albumin bound
Alternative Names: ABI-008; nab-docetaxelLatest Information Update: 18 Dec 2021
Price :
$50
*
At a glance
- Originator Abraxis BioScience
- Developer Celgene Corporation
- Class Antineoplastics; Radiopharmaceutical diagnostics; Small molecules; Taxanes
- Mechanism of Action Tubulin inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Breast cancer; Prostate cancer
Most Recent Events
- 01 Jan 2013 Discontinued - Phase-I/II for Breast cancer in USA (IV)
- 01 Jan 2013 Discontinued - Phase-I/II for Prostate cancer in USA (IV)
- 09 May 2011 Abraxis BioScience completes enrolment in its phase I/II trial for Prostate cancer in USA (NCT00477529)